Every Form 4 that Clover Health Investments, Corp (CLOV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLOV filings page.
Clover Health Investments Chief Financial Officer Peter J. Kuipers reported a routine tax-related share withholding. On January 29, 2026, 156,856 shares of Class A Common Stock were automatically withheld at $2.31 per share to cover tax obligations from vesting restricted stock units.
This withholding relates to 6.25% of the original time-based RSU grant awarded on April 29, 2024. After the transaction, Kuipers beneficially owned 5,758,353 Class A shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to his continued service.
Clover Health Investments CEO Andrew Toy reported an automatic share withholding to cover taxes tied to vesting stock units. On January 15, 2026, 60,764 shares of Class A common stock were withheld at $2.81 per share in connection with the vesting of 6.25% of a restricted stock unit (RSU) grant originally awarded on October 15, 2024.
Following this tax withholding, Toy directly beneficially owned 9,508,725 Class A shares. The remaining RSUs from the October 2024 grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, contingent on Toy’s continued service with the company.
Clover Health Investments (CLOV) filed a Form 4 detailing an automatic tax withholding transaction for its General Counsel & Secretary, Karen M. Soares. On January 15, 2026, 11,686 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this withholding, Soares beneficially owned 1,210,679 shares of Class A common stock in direct ownership form.
The footnote explains that this withholding relates to the vesting of 6.25% of an RSU grant awarded on October 15, 2024. The remaining RSUs from this grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, assuming Soares continues in service through each vesting date.
Clover Health Investments, Corp. CEO Conrad Wai reported an automatic share withholding related to restricted stock vesting. On January 15, 2026, 25,868 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of 6.25% of a prior RSU grant made on October 15, 2024.
After this tax withholding, Wai beneficially owned 1,025,806 Class A shares directly. In addition, a trust for the benefit of his family, of which he is a co‑trustee, held 1,610,482 Class A shares indirectly. The remaining RSUs from the 2024 grant are scheduled to vest quarterly in equal 6.25% installments through October 15, 2028, subject to his continued service.
Clover Health Investments, Corp. reported insider transactions by CEO, Medicare Advantage Jamie L. Reynoso in Class A Common Stock. On January 15, 2026, 14,732 shares were automatically withheld at $2.81 per share to cover tax obligations tied to the vesting of 6.25% of previously granted RSUs, which continue to vest quarterly at 6.25% through October 15, 2028, subject to continued service.
On January 20, 2026, Reynoso sold 4,597 shares at a weighted average price of $2.58 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. Following these transactions, she directly owns 2,737,700 shares of Class A Common Stock.
Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported routine share withholding to cover taxes on vested RSUs. On January 15, 2026, 18,076 shares of Class A common stock at $2.81 per share were automatically withheld to satisfy tax obligations tied to the vesting of 6.25% of RSUs granted on October 15, 2024, leaving 2,210,507 shares beneficially owned directly. On January 18, 2026, an additional 36,923 shares at $2.54 per share were withheld for taxes on another 6.25% RSU vesting from a July 18, 2022 grant, after which Priest directly beneficially owned 2,173,584 shares of Class A common stock.
Clover Health Investments director and 10% owner Vivek Garipalli reported a large RSU vesting and related share movements. On January 7, 2026, the final 20% of a restricted stock unit grant from January 7, 2021 vested. This delivered 1,686,750 shares of Class B common stock and triggered the automatic conversion of 1,655,949 Class B shares into the same number of Class A shares, which were withheld by the company to satisfy tax obligations at a value of $2.59 per share.
Following these transactions, Garipalli directly held 1,856,247 shares of Class A common stock and 8,591,093 shares of Class B common stock75,694,143 shares of Class B common stock through NJ Healthcare Investments, LLC and 11,500,000 shares of Class B common stock through Caesar Clover, LLC, with each Class B share convertible into one Class A share.
Clover Health Investments, Corp. reported that director Demetrios L. Kouzoukas received an equity award in the form of restricted stock units. On January 6, 2026, he acquired 79,365 shares of Class A common stock at a price of $0 per share, reflecting the grant of time-based RSUs rather than a cash purchase.
These RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that vesting date. After this grant, Kouzoukas beneficially owned 605,980 shares of Class A common stock, held directly.
Clover Health Investments, Corp. director reports stock-based award. Director Carladenise Armbrister Edwards received 79,365 shares of Class A Common Stock on January 6, 2026, as part of a time-based restricted stock unit (RSU) grant at a price of $0 per share. These RSUs represent stock that will vest in full on the first anniversary of January 6, 2026, if she continues serving as a director through that date. Following this grant, she beneficially owns 352,592 shares of Class A Common Stock in total, reported as directly held.
Clover Health Investments director Anna U. Loengard reported an equity grant and updated share holdings. On January 6, 2026, she acquired 79,365 shares of Class A Common Stock at $0, representing time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, if she continues to serve as a director through that date. Following this award, she beneficially owns 527,456 Class A shares directly. She also reports indirect beneficial ownership of 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian.
Clover Health Investments, Corp. director William G. Robinson Jr reported an equity award of 79,365 shares of Class A common stock on January 6, 2026. These shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that date. The award was recorded at a price of $0 per share, reflecting a grant rather than an open-market purchase. After this grant, Robinson beneficially owned a total of 597,987 shares of Class A common stock in direct ownership.
Clover Health Investments, Corp. director Thomas L. Tran reported an equity award of Class A Common Stock. On January 6, 2026, he was granted 79,365 shares of Class A Common Stock, received as time-based restricted stock units (RSUs) at a price of $0 per share, meaning this was a compensatory grant rather than an open-market purchase.
According to the filing, these RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as Tran continues to serve as a director through that vesting date. After this award, Tran beneficially owns 180,029 shares of Class A Common Stock directly. This filing reflects routine director compensation in the form of equity.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO for Medicare Advantage, reported a small insider sale of Class A common stock. On January 7, 2026, Reynoso sold 2,102 shares at a weighted average price of $2.53 per share in an open-market transaction. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025, which automates trades according to preset instructions. After this transaction, Reynoso directly beneficially owned 2,757,029 shares of Clover Health Class A common stock.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.
Clover Health Investments, Corp.'s CEO for Medicare Advantage reported automatic share withholding transactions related to restricted stock unit vesting.
On December 14, 2025 and December 15, 2025, 12,567 and 8,691 shares of Class A Common Stock, respectively, were withheld at $2.7 per share to cover tax obligations when 6.25% quarterly tranches of time-based RSU grants from March 14, 2022 and September 16, 2022 vested. After these transactions, the officer directly beneficially owns 2,772,153 shares of Class A Common Stock, and the remaining RSUs continue to vest quarterly in 6.25% installments through March 14, 2026 and September 15, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider share withholding related to restricted stock vesting. On December 14, 2025, an officer serving as CEO, Counterpart Health had 98,411 shares of Class A common stock automatically withheld at $2.7 per share to cover tax obligations when a portion of previously granted restricted stock units vested.
After this transaction, the reporting person beneficially owned 1,051,674 Class A shares directly and 1,610,482 shares indirectly through a trust. The withheld shares correspond to 6.25% of the original time-based RSU grant made on March 14, 2022, which continues to vest in equal 6.25% quarterly installments through March 14, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider equity transaction by an officer serving as General Counsel & Secretary. On December 15, 2025, 6,404 shares of Class A common stock were withheld to cover tax obligations triggered by the vesting of time-based restricted stock units (RSUs).
The withheld shares correspond to 6.25% of the original RSU grant made on September 15, 2022. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments, with a final vesting date on September 15, 2026, subject to the reporting person’s continued service. Following this tax-withholding event, the reporting person beneficially owns 1,222,365 Class A shares directly.
Clover Health Investments Corp. insider tax withholding transaction
A Clover Health Investments Corp. officer, serving as General Counsel and Secretary, reported an automatic share withholding related to restricted stock units. On November 14, 2025, 7,459 shares of Class A common stock were withheld at a price of $2.47 per share to cover tax obligations triggered by the vesting of time-based restricted stock units granted on February 14, 2022. After this transaction, the reporting person beneficially owned 1,228,769 shares of Class A common stock. The underlying restricted stock units vest in quarterly installments of 6.25%, with the final vesting date scheduled for February 14, 2026, conditioned on continued service.
Clover Health (CLOV) reported an insider Form 4 for CEO and Director Andrew Toy. On 11/08/2025, 85,535 shares of Class A common stock were withheld at $2.67 per share under transaction code F, reflecting automatic share withholding to cover taxes upon RSU vesting.
The vesting represented 6.25% of RSUs granted on 08/08/2022. Following the transaction, Toy beneficially owns 9,837,447 shares directly. The remaining RSUs vest quarterly in equal 6.25% installments through 08/08/2026, subject to continued service.
Clover Health Investments (CLOV): insider transaction disclosed. Officer Jamie L. Reynoso (CEO, Medicare Advantage) sold 30,385 shares of Class A common stock at a weighted average price of $3.58 on November 4, 2025, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owned 2,793,411 shares directly. The sale was executed in multiple trades at prices ranging from $3.49 to $3.67, and the reporting person undertakes to provide detailed trade breakdowns upon request.
Clover Health Investments (CLOV) disclosed a Form 4 for an officer (CEO of Home Care) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, the company automatically withheld 86,610 and 25,081 Class A shares at $3.53 per share to cover taxes as restricted stock units vested.
The filing notes these were tied to the final 50% of earned performance-based RSUs from an award dated October 31, 2023, and the final 12.5% of another RSU tranche vesting the same day. Following these transactions, the reporting person directly beneficially owned 2,228,583 Class A shares.
Clover Health Investments (CLOV) disclosed a Form 4 for officer Karen M. Soares (General Counsel & Secretary) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, two Code F entries were reported: 131,521 shares of Class A common stock and 38,086 shares were automatically withheld at a price of $3.53 per share to cover taxes.
The withholding related to performance-based RSUs granted on 10/31/2023, with one-half of earned units settled on 09/13/2024 and the remaining half vesting on 10/31/2025. An additional tranche representing the final 12.5% of RSUs from the same grant also vested on 10/31/2025. Following these transactions, Soares directly beneficially owned 1,236,228 Class A shares.
Clover Health (CLOV) reported insider activity by its officer (CEO, Medicare Advantage), Jamie L. Reynoso. On 10/31/2025, two transactions with code F reflected shares of Class A common stock automatically withheld to cover taxes upon RSU vesting: 101,917 shares related to performance-based RSUs and 29,513 shares related to time-based RSUs, each at $3.53.
Following these withholdings, the reporting person directly beneficially owned 2,823,796 shares. These entries reflect tax withholding tied to previously awarded RSUs and do not represent open-market sales.
Clover Health Investments (CLOV) insider filing: Officer Conrad Wai reported tax-withholding transactions tied to RSU vesting. On 10/31/2025, 96,448 shares of Class A common stock were withheld at $3.53 per share to satisfy taxes for the final 50% of earned performance-based RSUs from an award dated 10/31/2023. On the same date, 27,930 shares were withheld at $3.53 due to vesting of the final 12.5% of time-based RSUs.
Following these transactions, the reporting person beneficially owned 1,150,085 Class A shares directly. In addition, 1,610,482 shares were held indirectly by a family trust for which the reporting person serves as co-trustee. The filing identifies the reporting person as an officer (CEO, Counterpart Health).
Clover Health (CLOV) reported an insider equity transaction by its Chief Financial Officer. On October 29, 2025, 217,382 shares of Class A common stock were automatically withheld at $3.64 per share to cover taxes upon the vesting of a portion of previously granted RSUs.
The vesting represented 6.25% of the original time‑based RSU grant made on April 29, 2024. Following the transaction, the reporting person directly beneficially owns 5,915,209 shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to continued service.
Clover Health (CLOV) reported an insider transaction by its CEO, Medicare Advantage, Jamie L. Reynoso. On 10/17/2025, Reynoso sold 16,514 Class A shares in open market transactions at a $2.69 weighted average price, with trade prices ranging from $2.65 to $2.72. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owns 2,955,226 shares, held directly.
Clover Health (CLOV) executive Brady Priest (CEO of Home Care) reported a tax‑withholding transaction on October 18, 2025. The filing shows 48,305 shares of Class A common stock were automatically withheld at $2.71 per share upon RSU vesting (Transaction Code F), leaving 2,340,274 shares beneficially owned directly.
The shares relate to vesting of 6.25% of time‑based RSUs granted on July 18, 2022. The remaining RSUs have a final vesting date on July 18, 2026, contingent on continued service.
Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. An officer (CEO of Home Care) had 82,778 shares of Class A Common Stock automatically withheld at $2.8 on 10/15/2025 to cover taxes from restricted stock unit (RSU) vesting (Transaction Code F).
Following the withholding, the reporting person directly beneficially owns 2,388,579 shares. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025, with the remainder vesting quarterly in 6.25% increments through 10/15/2028, subject to continued service.
Clover Health (CLOV) reported an insider transaction by CEO and Director Andrew Toy. On 10/15/2025, 242,580 shares of Class A Common Stock were withheld at $2.8 per share (transaction code F) to cover tax obligations arising from RSU vesting. Following this administrative withholding, Toy beneficially owns 9,922,982 shares directly.
The withheld shares relate to RSUs granted on 10/15/2024, with 25% vesting on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. Officer Jamie L. Reynoso (CEO, Medicare Advantage) had 71,432 shares of Class A Common Stock automatically withheld on 10/15/2025 to cover taxes from RSU vesting, at a transaction price of $2.8 per share (Code F).
Following this tax withholding, the insider beneficially owns 2,971,740 shares, held directly. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Clover Health Investments (CLOV) reported an insider equity transaction. The company’s General Counsel & Secretary filed a Form 4 showing a transaction on 10/15/2025 coded “F,” reflecting 57,249 Class A shares automatically withheld at $2.8 per share to satisfy taxes from RSU vesting. Following the transaction, the reporting person beneficially owns 1,405,835 shares directly.
The withholding stemmed from the vesting of 25% of RSUs granted on 10/15/2024. The remaining RSUs vest quarterly in equal 6.25% installments, with a final vesting date on 10/15/2028, subject to continued service.
Clover Health Investments (CLOV): Officer Form 4 filing. A company officer reported an automatic share withholding for taxes tied to RSU vesting. On 10/15/2025, 92,181 shares of Class A common stock were withheld (code F) at $2.80 due to the vesting of 25% of RSUs granted on 10/15/2024.
After this tax withholding, the officer reported 1,274,463 shares beneficially owned directly, plus 1,610,482 shares held indirectly by a family trust. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Jamie L. Reynoso, listed as CEO, Medicare Advantage, reported two Section 16 transactions. On 10/03/2025 8,706 shares of Class A common stock were withheld to cover taxes upon vesting of 6.25% of restricted stock units granted on 01/03/202301/03/2027. On 10/07/2025 the reporting person sold 2,012 shares under a Rule 10b5-1 trading plan adopted on 03/13/2025 at $2.65 per share. After these transactions the reporting person beneficially owned 3,043,172 Class A shares. The Form 4 discloses routine tax withholding on RSU vesting and a planned sale under an established trading plan.
Andrew Toy, who is listed as both Chief Executive Officer and a director of Clover Health Investments, Corp. (CLOV), reported a withholding disposition of 308,950 shares of Class A common stock on 10/01/2025 at a price of $2.62 per share to cover tax obligations arising from vested restricted stock units. After this withholding, the reporting person beneficially owns 10,165,562 shares. The filing explains these shares correspond to the automatic withholding for the vesting of 6.25% of RSUs originally granted on 01/01/2023; the remaining RSUs vest quarterly in equal 6.25% installments with a final vesting on 01/01/2027, subject to continued service.